CN113476458A - Vitamin D3 compound and preparation method and application thereof - Google Patents
Vitamin D3 compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN113476458A CN113476458A CN202110954534.8A CN202110954534A CN113476458A CN 113476458 A CN113476458 A CN 113476458A CN 202110954534 A CN202110954534 A CN 202110954534A CN 113476458 A CN113476458 A CN 113476458A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- compound
- antioxidant
- porous carrier
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a vitamin D3 compound and a preparation method and application thereof, belonging to the technical field of pharmaceutical preparations. The vitamin D3 compound comprises vitamin D3, a porous carrier material and an antioxidant; the antioxidant and the vitamin D3 are loaded in the porous carrier material together, so that the stability of the vitamin D3 can be effectively improved, and the vitamin D3 is prevented from being degraded in the preparation production process and the product storage process. The invention provides a prescription composition and a preparation method of the vitamin D3 compound. The vitamin D3 compound can be further prepared into granules, tablets and chewable tablet dosage forms, and the content of vitamin D3 in the compound can be adjusted according to the needs so as to meet the requirement of content uniformity of vitamin D3 in preparation products.
Description
Technical Field
The invention relates to the technical field of pharmaceutical preparations, in particular to a vitamin D3 compound and a preparation method and application thereof.
Background
Vitamin D3, also known as cholecalciferol, is the most important form of vitamin D group, and can regulate calcium and phosphorus metabolism in vivo, and has a wide range of biological functions, including increasing absorption of calcium and phosphorus by the body, promoting bone growth, and performing immunoregulatory action.
Vitamin D3 is unstable, and unsaturated double bonds in the structure are easily degraded under the conditions of illumination, oxidation, high temperature and the like; vitamin D3 content in the formulation product is extremely low (as low as a few parts per million), and content uniformity presents a significant challenge; therefore, due to the limitations of stability and content uniformity, the production of solid vitamin D3 formulations cannot be performed using a single vitamin D3 component, and it is necessary to develop the formulations as stable complexes, and the prior art vitamin D3 complex has a problem of poor stability.
Disclosure of Invention
In view of the above, the present invention aims to provide a vitamin D3 complex, and a preparation method and an application thereof. The vitamin D3 compound provided by the invention has good stability.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a vitamin D3 compound, which comprises the following components in percentage by mass: 30.1-1.0% of vitamin D, 0.5-6.0% of antioxidant and the balance of porous carrier material, wherein the antioxidant and the vitamin D3 are loaded in pores of the porous carrier material.
Preferably, the vitamin D3 composite also comprises solvent-type auxiliary materials, wherein the mass percentage of the solvent-type auxiliary materials in the vitamin D3 composite is less than or equal to 45%; the solvent-based auxiliary materials are loaded in pores of the porous carrier material; the solvent-based auxiliary materials comprise one or more of polyethylene glycol 400, soybean oil, medium-chain triglyceride and propylene glycol dicaprylate/dicaprate.
Preferably, the porous support material comprises one or more of gel silica, calcium silicate and magnesium aluminium silicate; the antioxidant comprises a water-soluble antioxidant and/or a fat-soluble antioxidant, the water-soluble antioxidant comprises one or more of sodium bisulfite, edetate disodium, sodium thiosulfate, vitamin C and L-arginine, and the fat-soluble antioxidant comprises one or more of vitamin E, butylated hydroxyanisole and butylated hydroxytoluene.
The invention also provides a preparation method of the vitamin D3 compound, which comprises the following steps:
mixing the vitamin D3 solution and the antioxidant solution with a porous carrier material, and adsorbing the vitamin D3 solution and the antioxidant solution into pores of the porous carrier material to obtain the vitamin D3 compound.
The invention also provides application of the vitamin D3 compound in the technical scheme or the vitamin D3 compound prepared by the preparation method in the technical scheme in preparation of granules, tablets or chewable tablets.
The invention provides a vitamin D3 compound, which comprises the following components in percentage by mass: 30.1-1.0% of vitamin D, 0.5-6.0% of antioxidant and the balance of porous carrier material, wherein the antioxidant and the vitamin D3 are loaded in pores of the porous carrier material. According to the invention, the porous carrier material is an amorphous particle, the liquid adsorption capacity is very strong, the excellent liquid adsorption capacity of the porous carrier material is utilized to prepare the vitamin D3 compound containing the antioxidant, the stability of vitamin D3 can be effectively improved, and the vitamin D3 is prevented from being degraded in the storage process or the production and storage processes of the preparation; the content of the vitamin D3 in the compound and the particle size of the compound can be adjusted according to the requirements of preparation prescription and process development so as to meet the requirements of vitamin D3 mixing uniformity and vitamin D3 content uniformity in the preparation.
Further, the porous carrier material used in the present invention comprises one or more of gel silica, calcium silicate and magnesium aluminum silicate, and the porous carrier material has a rich void structure inside particles, a high specific surface area and a high porosity.
The invention also provides a preparation method of the vitamin D3 compound in the technical scheme, and the preparation method is simple and easy to operate and has low dependence on equipment.
The vitamin D3 compound can be further prepared into calcium carbonate D3 preparations (such as granules, tablets or chewable tablets and the like) which have good stability and meet the requirement on the content uniformity of the vitamin D3.
Drawings
Fig. 1 is a scanning electron micrograph of the vitamin D3 complex prepared in example 1.
Detailed Description
The invention provides a vitamin D3 compound, which comprises the following components in percentage by mass: 30.1-1.0% of vitamin D, 0.5-6.0% of antioxidant and the balance of porous carrier material, wherein the antioxidant and the vitamin D3 are loaded in pores of the porous carrier material.
In the invention, the vitamin D3 compound preferably further comprises a solvent-based auxiliary material, the mass percentage of the solvent-based auxiliary material in the vitamin D3 compound is preferably less than or equal to 45%, and the solvent-based auxiliary material is preferably loaded in pores of the porous carrier material.
In the present invention, the solvent-borne adjuvants preferably include one or more of polyethylene glycol 400, soybean oil, medium chain triglycerides, and propylene glycol dicaprylate/dicaprate.
In the present invention, the porous support material preferably comprises one or more of gel silica, calcium silicate and magnesium aluminium silicate.
In the present invention, the antioxidant preferably includes a water-soluble antioxidant and/or a fat-soluble antioxidant, the water-soluble antioxidant more preferably includes one or more of sodium bisulfite, disodium edetate, sodium thiosulfate, vitamin C and L-arginine, and the fat-soluble antioxidant more preferably includes one or more of vitamin E, butylated hydroxyanisole and butylated hydroxytoluene.
The invention also provides a preparation method of the vitamin D3 compound, which comprises the following steps:
mixing the vitamin D3 solution and the antioxidant solution with a porous carrier material, and adsorbing the vitamin D3 solution and the antioxidant solution into pores of the porous carrier material to obtain the vitamin D3 compound.
According to the invention, the antioxidant is preferably mixed with the first solvent to obtain an antioxidant solution; mixing the vitamin D3 with a second solvent to obtain a vitamin D3 solution.
When the antioxidant is preferably only a water-soluble antioxidant, the preparation method of the vitamin D3 complex preferably comprises the following steps:
dissolving the water-soluble antioxidant in water to obtain a water-soluble antioxidant solution;
adding the water-soluble antioxidant solution into pores of a porous carrier material to obtain a wet water-soluble antioxidant-porous carrier composite;
placing the wet antioxidant-porous carrier compound in an oven, and drying at 40-60 ℃ to obtain a dried water-soluble antioxidant-porous carrier compound;
mixing the vitamin D3 with ethanol to obtain a vitamin D3 solution;
adding the vitamin D3 solution into the pores of the dried water-soluble antioxidant-porous carrier complex to obtain a moist vitamin D3 complex;
and (3) placing the wet vitamin D3 compound in an oven, and drying at 40-60 ℃ to obtain the vitamin D3 compound.
When the antioxidant is preferably only a fat-soluble antioxidant, the preparation method of the vitamin D3 complex preferably comprises the following steps:
mixing the vitamin D3, the fat-soluble antioxidant and ethanol to obtain a vitamin D3-antioxidant solution;
adding the vitamin D3-antioxidant solution into pores of the porous carrier material to obtain a wet vitamin D3 complex;
and (3) placing the wet vitamin D3 compound in an oven, and drying at 40-60 ℃ to obtain the vitamin D3 compound.
When the antioxidant preferably contains both the water-soluble antioxidant and the fat-soluble antioxidant, the preparation method of the vitamin D3 complex preferably comprises the following steps:
dissolving the water-soluble antioxidant in water to obtain a water-soluble antioxidant solution;
adding the water-soluble antioxidant solution into pores of a porous carrier material to obtain a wet water-soluble antioxidant-porous carrier composite;
placing the wet antioxidant-porous carrier compound in an oven, and drying at 40-60 ℃ to obtain a dried water-soluble antioxidant-porous carrier compound;
mixing the vitamin D3, the fat-soluble antioxidant and ethanol to obtain a vitamin D3-fat-soluble antioxidant solution;
adding the vitamin D3-fat-soluble antioxidant solution into pores of the dried water-soluble antioxidant-porous carrier composite to obtain a wet vitamin D3 composite;
and (3) placing the wet vitamin D3 compound in an oven, and drying at 40-60 ℃ to obtain the vitamin D3 compound.
When the vitamin D3 compound preferably contains solvent-based auxiliary materials, the preparation method of the vitamin D3 compound is consistent with the scheme, and only the difference is that the ethanol is replaced by the solvent-based auxiliary materials, and the step of drying at 40-60 ℃ in an oven is omitted.
The invention also provides application of the vitamin D3 compound in the technical scheme or the vitamin D3 compound prepared by the preparation method in the technical scheme in preparation of granules, tablets or chewable tablets.
In order to further illustrate the present invention, the vitamin D3 complex provided in the present invention, the preparation method and the use thereof are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1:
the raw materials for preparing the vitamin D3 complex are shown in Table 1.
Table 1 preparation of vitamin D3 complex as starting material in example 1
The preparation method comprises the following steps:
1) adding vitamin C into purified water, stirring and dissolving to obtain a vitamin C aqueous solution;
2) adding the vitamin C aqueous solution into the gel silicon dioxide powder, and stirring the powder while adding the solution so that the gel silicon dioxide can quickly and effectively adsorb the aqueous solution to obtain a wet vitamin C-gel silicon dioxide compound;
3) passing the compound prepared in step 2) through a No. 4 sieve, placing the sieved compound in an oven, drying at the temperature of 50 ℃ for 2h, and passing the dried compound through the No. 4 sieve to obtain a dried vitamin C-gel silicon dioxide compound;
4) adding vitamin D3 and vitamin E into ethanol, and stirring for dissolving to obtain solution; adding the solution into the vitamin C-gel silicon dioxide compound powder obtained in the step 3), and stirring the powder while adding the solution so that the compound can quickly and effectively adsorb the solution to obtain a wet vitamin D3 compound;
5) passing the vitamin D3 compound prepared in step 4) through a No. 4 sieve, placing the sieved vitamin D3 compound in an oven, drying at the temperature of 50 ℃ for 2h, and passing the dried compound through the No. 4 sieve to obtain the vitamin D3 compound.
The morphology of the compound was observed using a scanning electron microscope and the results are shown in FIG. 1. It can be seen that vitamin D3, vitamin C and vitamin E are all loaded in the pores of the gel silica.
Example 2:
the raw materials for preparing the vitamin D3 complex are shown in Table 2.
Table 2 preparation of vitamin D3 complex as starting material in example 2
The preparation method comprises the following steps:
1) adding vitamin C and edetate disodium into purified water, and stirring for dissolving to obtain water solution;
2) adding the aqueous solution prepared in the step 1) into magnesium aluminum silicate powder, and stirring the powder while adding the solution so that magnesium aluminum silicate can quickly and effectively adsorb the aqueous solution to obtain a wet vitamin C-edetate disodium-magnesium aluminum silicate compound;
3) sieving the compound prepared in the step 2) by a No. 4 sieve, placing the sieved compound in an oven, drying at the temperature of 50 ℃ for 2 hours, and sieving the dried compound by the No. 4 sieve to obtain a dried vitamin C-edetate disodium-magnesium aluminum silicate compound;
4) adding vitamin D3 and vitamin E into medium chain triglyceride, stirring for dissolving to obtain solution; adding the solution into the vitamin C-edetate disodium-magnesium aluminum silicate compound powder obtained in the step 3), and stirring the powder while adding the solution so that the compound can quickly and effectively adsorb the solution; and (4) sieving the prepared compound by a No. 4 sieve to obtain the vitamin D3 compound.
Example 3: comparative study of stability
The vitamin D3 complexes prepared in examples 1-2 above were subjected to stability tests with a commercially available vitamin D3 clathrate. The results are shown in table 3, and the comparison of the content of the three components and the change of related substances shows that the content is uniform and obviously changed, while the related substance level of the vitamin D3 compound prepared in examples 1-2 is significantly lower than that of the commercially available inclusion compound.
TABLE 3 comparison of the stability of vitamin D3 complexes prepared in examples 1-2 with commercially available vitamin D3 inclusion complexes
Example 4: preparation of calcium carbonate D3 chewable tablets based on vitamin D3 complex
The vitamin D3 complex prepared in example 2 was prepared into calcium carbonate D3 chewable tablets (batch: 1.5 ten thousand tablets/batch), three batches of products (201101, 201102 and 201103, respectively) were prepared, and content uniformity and stability were investigated with commercially available products as a comparison. And (2) carrying out wet granulation on the calcium carbonate and auxiliary materials of mannitol and povidone to obtain granules, sieving the wet granules with a 24-mesh sieve, sieving the dried dry granules with a 20-mesh sieve to carry out size stabilization, mixing the obtained calcium carbonate granules with the vitamin D3 compound, the essence and the magnesium stearate prepared in the example 2, and tabletting.
Content uniformity
The content uniformity test is carried out according to 0941 of the general rules of the four parts of the 2020 edition of Chinese pharmacopoeia, and the results are shown in Table 4, which shows that the calcium carbonate D3 chewable tablet prepared by the invention has good content uniformity of vitamin D3 (better than the commercially available product), meets the requirement that A +2.2S is less than or equal to 15, and meets the specifications of the pharmacopoeia.
TABLE 4 content uniformity comparison
| Batch number | A certain commercial product | 201101 | 201102 | 201103 |
| Average content (%) | 108.5 | 101.6 | 100.2 | 102.5 |
| A | 8.5 | 1.6 | 0.2 | 2.5 |
| S | 14.6 | 3.1 | 3.5 | 2.7 |
| A+2.2S | 40.62 | 8.42 | 7.90 | 8.44 |
Stability of
The results of stability studies on the D3 chewable tablets and the commercially available products prepared by the invention are shown in table 5, and it is shown that the calcium carbonate D3 chewable tablets and the commercially available products prepared by the invention have no obvious change in vitamin D3 content, but the vitamin D3 related substance level of the home-made preparation is significantly lower than that of the commercially available products.
TABLE 5 stability comparison
The results show that the vitamin D3 compound provided by the invention has good quality and can meet the requirements of vitamin D3 content uniformity and stability of a preparation product.
The foregoing is merely a preferred embodiment of the invention and is not intended to limit the invention in any manner. It should be noted that, for those skilled in the art, without departing from the principle of the present invention, several improvements and modifications can be made, and these improvements and modifications should also be construed as the protection scope of the present invention.
Claims (5)
1. The vitamin D3 compound is characterized by comprising the following components in percentage by mass: 30.1-1.0% of vitamin D, 0.5-6.0% of antioxidant and the balance of porous carrier material, wherein the antioxidant and the vitamin D3 are loaded in pores of the porous carrier material.
2. The vitamin D3 complex according to claim 1, further comprising a solvent-based adjuvant, wherein the mass percentage of the solvent-based adjuvant in the vitamin D3 complex is 45% or less, and the solvent-based adjuvant is loaded in the pores of the porous carrier material; the solvent-based auxiliary materials comprise one or more of polyethylene glycol 400, soybean oil, medium-chain triglyceride and propylene glycol dicaprylate/dicaprate.
3. Vitamin D3 complex according to claim 1 or 2, wherein the porous carrier material comprises one or more of gel silica, calcium silicate and magnesium aluminium silicate;
the antioxidant comprises a water-soluble antioxidant and/or a fat-soluble antioxidant, the water-soluble antioxidant comprises one or more of sodium bisulfite, edetate disodium, sodium thiosulfate, vitamin C and L-arginine, and the fat-soluble antioxidant comprises one or more of vitamin E, butylated hydroxyanisole and butylated hydroxytoluene.
4. A process for the preparation of vitamin D3 complex according to any one of claims 1 to 3, comprising the steps of:
mixing the vitamin D3 solution and the antioxidant solution with a porous carrier material, and adsorbing the vitamin D3 solution and the antioxidant solution into pores of the porous carrier material to obtain the vitamin D3 compound.
5. Use of the vitamin D3 complex according to any one of claims 1 to 3 or the vitamin D3 complex prepared by the preparation method according to claim 4 in the preparation of granules, tablets or chewable tablets.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110954534.8A CN113476458A (en) | 2021-08-19 | 2021-08-19 | Vitamin D3 compound and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110954534.8A CN113476458A (en) | 2021-08-19 | 2021-08-19 | Vitamin D3 compound and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113476458A true CN113476458A (en) | 2021-10-08 |
Family
ID=77946919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110954534.8A Pending CN113476458A (en) | 2021-08-19 | 2021-08-19 | Vitamin D3 compound and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113476458A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113952358A (en) * | 2021-11-24 | 2022-01-21 | 合肥远志医药科技开发有限公司 | Calcium carbonate and vitamin D3 composition and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105616441A (en) * | 2014-11-05 | 2016-06-01 | 澳美制药厂有限公司 | Calcium carbonate vitamin d3 tablet and preparation method thereof |
| CN108853516A (en) * | 2018-07-07 | 2018-11-23 | 成都迈德克科技有限公司 | A kind of functional load medicine calcium citrate |
| CN112569197A (en) * | 2020-12-25 | 2021-03-30 | 山东达因海洋生物制药股份有限公司 | Vitamin D3 composition and preparation method and application thereof |
| CN112641718A (en) * | 2020-12-25 | 2021-04-13 | 山东大学 | Taste-masking compound based on porous carrier and preparation method and application thereof |
-
2021
- 2021-08-19 CN CN202110954534.8A patent/CN113476458A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105616441A (en) * | 2014-11-05 | 2016-06-01 | 澳美制药厂有限公司 | Calcium carbonate vitamin d3 tablet and preparation method thereof |
| CN108853516A (en) * | 2018-07-07 | 2018-11-23 | 成都迈德克科技有限公司 | A kind of functional load medicine calcium citrate |
| CN112569197A (en) * | 2020-12-25 | 2021-03-30 | 山东达因海洋生物制药股份有限公司 | Vitamin D3 composition and preparation method and application thereof |
| CN112641718A (en) * | 2020-12-25 | 2021-04-13 | 山东大学 | Taste-masking compound based on porous carrier and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| ZANE TEMOVA RAKUSA ET AL.: "Comprehensive Stability Study of Vitamin D3 in Aqueous Solutions and Liquid Commercial Products", 《PHARMACEUTICS》 * |
| 王晋: "羟基维生素D3制剂的稳定化方法及其在透皮吸收制剂、化妆品等方面的应用", 《中国医药工业杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113952358A (en) * | 2021-11-24 | 2022-01-21 | 合肥远志医药科技开发有限公司 | Calcium carbonate and vitamin D3 composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1146405C (en) | Free-flowing dried particles | |
| CN103705485B (en) | Composite for treating myelodysplastic syndrome and preparation method thereof | |
| CN107875136B (en) | Amoxicillin medicinal preparation and preparation method thereof | |
| Zhang et al. | Resveratrol nanodispersion with high stability and dissolution rate | |
| CN101524377A (en) | Composite of wall-breaking lucidum spore powder and cyclodextrin and preparation method thereof | |
| JPH06219952A (en) | Solid medical composition | |
| CN108403664B (en) | Liquid crystal gel nanoparticles capable of encapsulating drugs with different polarities and preparation method thereof | |
| CN113476458A (en) | Vitamin D3 compound and preparation method and application thereof | |
| TW201311236A (en) | Celecoxib solid dispersion and its preparation method | |
| JP7196239B2 (en) | Pharmaceutical composition containing solid dispersion and oil dispersion of ED-71 | |
| CN104162168A (en) | Stable paricalcitol pharmaceutical composition and preparation method thereof | |
| CN105616441A (en) | Calcium carbonate vitamin d3 tablet and preparation method thereof | |
| JP2016164147A (en) | Extract powder | |
| Wang et al. | Release of paclitaxel from polylactide-co-glycolide (PLGA) microparticles and discs under irradiation | |
| CN103142525B (en) | Olanzapine gastric soluble tablet and preparation method thereof | |
| CN1857676A (en) | Zedoary oil microcapsule preparation and its preparing process | |
| AU2021106183A4 (en) | Vitamin d3 complex and preparation method and application thereof | |
| CA2047027C (en) | Tablet and granulate containing mesna as active substance | |
| CN106924193A (en) | A kind of high porosity Foradil Aerolizer formoterol fumarate carrier and its over-saturation synthetic method and application | |
| CN112569197A (en) | Vitamin D3 composition and preparation method and application thereof | |
| EP3305287B1 (en) | Powder composition containing oily substance | |
| JP6073843B2 (en) | Method for producing orally disintegrating tablet excellent in hardness and disintegration, and orally disintegrating tablet produced by the production method | |
| CN112715943A (en) | Glucosamine chondroitin tablet containing active peptide and organic calcium and preparation method thereof | |
| RU2662577C1 (en) | Method for obtaining composition based on alumina | |
| CN107320440B (en) | Sulforaphane-containing gastric retention composition and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |